GSA Capital Partners LLP Invests $3.08 Million in Natera, Inc. $NTRA

Key Points

• GSA Capital Partners opened a new $3.08 million position in Natera during the second quarter, while institutional investors and hedge funds collectively own 99.90% of the company.
• Natera reported quarterly revenue of $752.75 million, up 37.7% year over year and above estimates, while its adjusted loss of $0.47 per share narrowly beat forecasts.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $319.38; shares recently traded at $309.93, near their 12-month high of $326.03.

GSA Capital Partners LLP purchased a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the second quarter, according to its most recent filing with the SEC. The fund purchased 11,336 shares of the medical research company's stock, valued at approximately $3,077,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Coatue Management LLC boosted its holdings in Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock worth $603,270,000 after purchasing an additional 2,463,008 shares during the period. Wellington Management Group LLP raised its holdings in shares of Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares during the period. Norges Bank bought a new position in shares of Natera in the 4th quarter worth about $372,398,000. JPMorgan Chase & Co. lifted its position in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock worth $2,944,800,000 after buying an additional 1,225,420 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in shares of Natera by 39.0% in the 3rd quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company's stock valued at $386,338,000 after buying an additional 673,315 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Trading Down 0.3%

Shares of NASDAQ NTRA opened at $309.93 on Friday. The stock has a 50 day simple moving average of $263.76 and a 200-day simple moving average of $226.40. The company has a market cap of $44.67 billion, a PE ratio of -227.89 and a beta of 1.51. Natera, Inc. has a 12-month low of $156.71 and a 12-month high of $326.03.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the previous year, the business earned ($0.74) EPS. The firm's revenue for the quarter was up 37.7% on a year-over-year basis. Sell-side analysts forecast that Natera, Inc. will post -1.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Natera in a research note on Friday, July 17th. Zacks Research upgraded Natera from a "strong sell" rating to a "hold" rating in a research report on Wednesday. Leerink Partners set a $330.00 price target on Natera in a report on Friday, August 7th. UBS Group set a $260.00 price objective on Natera in a research report on Wednesday, June 24th. Finally, BTIG Research upped their price objective on Natera from $290.00 to $320.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and an average target price of $319.38.

Insider Activity at Natera

In related news, CFO Michael Burkes Brophy sold 478 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total value of $131,077.16. Following the completion of the transaction, the chief financial officer owned 51,637 shares in the company, valued at $14,159,898.14. This represents a 0.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 295 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $267.99, for a total transaction of $79,057.05. Following the sale, the insider owned 183,774 shares in the company, valued at $49,249,594.26. This trade represents a 0.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 181,045 shares of company stock valued at $41,330,968 in the last ninety days. Company insiders own 5.05% of the company's stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source